186 related articles for article (PubMed ID: 33931953)
1. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
Vora B; Brackman DJ; Zou L; Garcia-Cremades M; Sirota M; Savic RM; Giacomini KM
Clin Transl Sci; 2021 Jul; 14(4):1431-1443. PubMed ID: 33931953
[TBL] [Abstract][Full Text] [Related]
2. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
3. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol.
Brackman DJ; Yee SW; Enogieru OJ; Shaffer C; Ranatunga D; Denny JC; Wei WQ; Kamatani Y; Kubo M; Roden DM; Jorgenson E; Giacomini KM
Clin Pharmacol Ther; 2019 Sep; 106(3):623-631. PubMed ID: 30924126
[TBL] [Abstract][Full Text] [Related]
5. BCRP/
Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.
Nakamura M; Fujita K; Toyoda Y; Takada T; Hasegawa H; Ichida K
Drug Metab Pharmacokinet; 2018 Feb; 33(1):77-81. PubMed ID: 29342419
[TBL] [Abstract][Full Text] [Related]
7. [ROLE OF SLC2A9 AND ABCG2 GENE POLYMORPHISMS IN ORIGIN OF HYPERURICEMIA AND GOUT].
Fadieieva A; Prystupa L; Pogorelova O; Kirichenko N; Dudchenko I
Georgian Med News; 2016 Mar; (252):79-83. PubMed ID: 27119840
[TBL] [Abstract][Full Text] [Related]
8. ABCG2/BCRP dysfunction as a major cause of gout.
Matsuo H; Takada T; Ichida K; Nakamura T; Nakayama A; Suzuki H; Hosoya T; Shinomiya N
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1117-28. PubMed ID: 22132966
[TBL] [Abstract][Full Text] [Related]
9. Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.
Toyoda Y; Pavelcová K; Bohatá J; Ješina P; Kubota Y; Suzuki H; Takada T; Stiburkova B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669292
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Chu WY; Annink KV; Nijstad AL; Maiwald CA; Schroth M; Bakkali LE; van Bel F; Benders MJNL; van Weissenbruch MM; Hagen A; Franz AR; Dorlo TPC; Allegaert K; Huitema ADR;
Clin Pharmacokinet; 2022 Feb; 61(2):321-333. PubMed ID: 34617261
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
[TBL] [Abstract][Full Text] [Related]
12. ABCG2 as a therapeutic target candidate for gout.
Fujita K; Ichida K
Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
[TBL] [Abstract][Full Text] [Related]
13. ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol.
Stamp LK; Wallace M; Roberts RL; Frampton C; Miner JN; Merriman TR; Dalbeth N
Drug Metab Pharmacokinet; 2018 Dec; 33(6):241-242. PubMed ID: 30274827
[No Abstract] [Full Text] [Related]
14. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
[TBL] [Abstract][Full Text] [Related]
15. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
Imai Y; Nakane M; Kage K; Tsukahara S; Ishikawa E; Tsuruo T; Miki Y; Sugimoto Y
Mol Cancer Ther; 2002 Jun; 1(8):611-6. PubMed ID: 12479221
[TBL] [Abstract][Full Text] [Related]
16. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
Roberts RL; Wallace MC; Phipps-Green AJ; Topless R; Drake JM; Tan P; Dalbeth N; Merriman TR; Stamp LK
Pharmacogenomics J; 2017 Mar; 17(2):201-203. PubMed ID: 26810134
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.
Wen CC; Yee SW; Liang X; Hoffmann TJ; Kvale MN; Banda Y; Jorgenson E; Schaefer C; Risch N; Giacomini KM
Clin Pharmacol Ther; 2015 May; 97(5):518-25. PubMed ID: 25676789
[TBL] [Abstract][Full Text] [Related]
18. Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
Sobek KM; Cummings JL; Bacich DJ; O'Keefe DS
Exp Cell Res; 2017 May; 354(1):40-47. PubMed ID: 28300564
[TBL] [Abstract][Full Text] [Related]
19. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
20. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
